NeuroPace grows revenue 22% with 77% gross margin, but tight liquidity and DIXI wind‑down loom

NeuroPace, Inc. (NASDAQ: NPCE) - quick read on what's happening inside the company and the income statement.

Snapshot - facts & figures (as reported, all $ in thousands unless noted)

* Q2 2025 revenue: $23,520 (up 22% vs Q2 2024); 6‑month revenue: $46,044 (up 23% YoY).

* Q2 2025 gross profit: $18,132; gross margin: 77.1% (Q2 2024: 73.4%). 6‑month gross margin: 77.0% (2024: 73.5%).

* Q2 2025 net loss: $(8,651); six months loss: $(15,240). Net loss per share Q2: $(0.26); six months: $(0.47).

* Cash & cash equivalents: $22,857; short‑term investments: $39,284 - total cash + short‑term investments ≈ $62.1M.

* Accounts receivable: $13,554; Inventory: $16,346.

* Total assets: $106,114; total liabilities: $86,676; stockholders' equity: $19,438.

* Long‑term debt (net): $58,616 (MidCap Term Loan funded June 2025). CRG Term Loan repaid in June 2025; loss on extinguishment $527 recorded.

* Follow‑on equity: 7,475,000 shares sold in Feb 2025 at $10.00; net proceeds $69.7M. $49.5M used to repurchase 5,270,845 shares from KCK Ltd.

* Weighted average shares (Q2): 32,863,031. Shares outstanding (6/30/25): 33,044,371.

* Trailing 12‑month net RNS System revenue (6/30/25): $71.6M.

* MidCap covenant: Applicable Liquidity Threshold ≥ $60.0M until 6/30/2027 (company in compliance as of 6/30/25).

What's moving inside the company

* Commercial momentum: Revenue growth driven by higher RNS System unit sales and DIXI product sales; gross margin improved to ~77% thanks to higher production volume and lower fixed costs per unit.

* Capital actions: Feb 2025 follow‑on raised $69.7M; used a large slice to repurchase a strategic holder's shares. ATM program terminated in Feb 2025.

* Financing: Replaced CRG facility with a $60M MidCap Term Loan in June 2025; mid‑term loan bears SOFR+5.5% (SOFR floor 2.0%); revolver undrawn.

* Clinical / regulatory: NAUTILUS generalized‑epilepsy study reported mixed 1‑year results (primary effectiveness not met overall; positive subset results). Company expects to file for expanded FDA label in H2 2025.

* Distribution change: Exclusive DIXI distribution agreement not renewed (expires 9/30/25), creating a wind‑down period and future revenue loss from that line.

Income statement - positives

* Top‑line growth: Revenue +22% QoQ (Q2) and +23% YTD - shows commercial traction.

* Gross margin expansion: 77.1% in Q2 vs 73.4% a year ago - scale in manufacturing is improving unit economics.

* Reduced interest expense: Interest expense down slightly after refinancing (CRG repaid, MidCap rate lower than previous effective CRG rate).

Income statement - negatives / risks

* Continued operating losses: Q2 net loss worsened to $(8.65M) (vs $(7.51M) prior year). Six‑month loss improved slightly but still $(15.24M).

* Rising operating spend: Operating expenses increased - Sales & Marketing +23% (Q2) and R&D +13% (Q2); G&A up 34% in Q2 driven by one‑time severance/transition costs and higher personnel costs.

* Reliance on non‑recurring capital actions: Follow‑on proceeds funded cash balance; without continued equity or other financing, runway would depend on improved cash generation and covenant compliance.

* One‑time items hurting near‑term P&L: $0.5M loss on CRG extinguishment and unrealized short‑term investment losses contributed to other expense.

* NIH grant timing: Grant-funded reductions to R&D decreased (less offset), increasing reported R&D expense in 2025.

Cash flow & liquidity - clearest takeaways

* Operating cash burn improved modestly: net cash used in operations YTD $9.6M (vs $11.4M prior year YTD).

* Liquidity cushion but covenant tightness: Cash + short‑term investments ≈ $62.1M - just above the MidCap covenant threshold ($60.0M) through 2027. Trailing RNS revenue ($71.6M) currently satisfies related covenant tests, but margins of safety are narrow.

* Debt profile: MidCap Term Loan principal due in one installment at maturity (6/4/2030); aggregate future nominal payments disclosed (~$91.7M gross), net reported carrying amount $58,616.

Operational notes / inventory

* Inventory up to $16.3M (raw materials + finished goods) - supports higher procedure volume but ties capital into stock.

* Receivables modest at $13.6M; no single customer >10% of revenues - limited customer concentration by revenue.

Near‑term catalysts & watch‑list (what investors should watch)

* FDA label expansion filing (planned H2 2025) - positive approval would materially expand addressable market.

* DIXI wind‑down (expires 9/30/25) - expect near‑term revenue contribution to fade after wind‑down window; monitor revenue mix and margin impact.

* Covenant monitoring - continued compliance with MidCap liquidity and trailing revenue tests; liquidity falling below thresholds would require corrective financing and raise going‑concern questions.

* Procedure volumes and margin trajectory - continued margin improvement depends on higher RNS unit sales and favorable product mix.

* Cash burn versus fundraising cadence - how management uses remaining cash and whether further equity/debt is needed.

Bottom line

NeuroPace is growing revenue and improving gross margins as RNS unit sales scale, and it executed a financing/refinancing package (follow‑on equity + MidCap term loan) that improved near‑term liquidity. The company still runs an operating loss, has rising operating expenses, and faces near‑term headwinds from the planned end of the DIXI distribution agreement and tight covenant thresholds. The next 6-12 months will hinge on procedure growth, margin progress and successful management of liquidity and covenants while the firm pursues FDA label expansion.

If you want, I can convert this into a one‑page investor summary with charts (cash, revenue, margins, debt timeline) or a concise risks & opportunities memo focused on the covenant and label‑expansion scenarios.